<DOC>
	<DOCNO>NCT00158860</DOCNO>
	<brief_summary>Genital herpes ( GH ) commonly occur sexually transmit disease cause herpes simplex virus ( HSV ) . There two type HSV , type 1 ( HSV-1 ) type 2 ( HSV-2 ) ; cause GH , although latter much likely produce frequent recurrence GH lesion . Evidence suggest advantage use suppressive vs. episodic treatment , include increase interval pain discomfort genital herpes recurrence . Therefore , study collect safety efficacy data suppressive therapy valaciclovir subject newly diagnose HSV-2 genital herpes .</brief_summary>
	<brief_title>A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion criterion : In overall general good health . Females enter participate study nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) childbearing potential , negative pregnancy test ( urine ) screen agrees use GSK stipulate contraceptive method . Must newly diagnose first recognize episode GH time Screening Visit within 3 month prior Screening Visit . Exclusion criterion : Known suspect immunocompromised ( e.g. , subject receive immunosuppressive therapy chemotherapy malignancy , seropositive HIV ) . Received investigational drug 30 day prior study . Receiving systemic antiviral immunomodulatory treatment . Must receive systemic antiviral treatment ( e.g. , valaciclovir , Famvir ( famciclovir ) , acyclovir , lysine ) within 3 day start study drug immunomodulatory treatment 30 day start study drug . Clinically significant impair renal function define creatinine clearance &lt; 30 ml/min , calculate use CockcroftGault formula . Clinically significant impair hepatic function define ALT ( alanine transaminase ) level &gt; 5 time normal upper limit . Subjects active liver disease . Known hypersensitive acyclovir , famciclovir , ganciclovir component valaciclovir formulation . Known resistance acyclovir , valaciclovir , penciclovir , famciclovir , ganciclovir valganciclovir . Subjects malabsorption vomit syndrome gastrointestinal dysfunction might impair drug pharmacokinetics . Women contemplate pregnancy within duration study drug dose period . Women pregnant and/or nursing mother Current history alcohol drug abuse . Received suppressive ( daily ) therapy genital herpes prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>valaciclovir</keyword>
	<keyword>genital herpes</keyword>
	<keyword>HSV-2</keyword>
	<keyword>Valtrex</keyword>
	<keyword>suppression</keyword>
</DOC>